Description: Lenvima is a medication that comes in the form of capsules, each containing 10 mg of the active ingredient, lenvatinib. Lenvatinib is a tyrosine kinase inhibitor used in the treatment of certain cancers. These capsules are designed for oral administration and are an integral part of cancer therapy under the guidance of a qualified healthcare professional.

Composition: Each Lenvima capsule contains 10 mg of lenvatinib as the active pharmaceutical ingredient. Inactive ingredients may include various excipients such as fillers, binders, and coatings to ensure the stability and proper formulation of the capsule.

Uses: Lenvima (lenvatinib) is prescribed for the treatment of:

1. Differentiated Thyroid Cancer (DTC): Lenvima is indicated for the treatment of locally recurrent or metastatic DTC that is refractory to radioactive iodine.
2. Renal Cell Carcinoma (RCC): Lenvima, in combination with another medication, is used for the treatment of advanced renal cell carcinoma.
3. Hepatocellular Carcinoma (HCC): Lenvima is indicated for the first-line treatment of advanced hepatocellular carcinoma.

How to Use: Lenvima capsules are taken orally with water. The healthcare provider will prescribe a specific dosage and provide instructions on when and how to take the medication. It is crucial to follow the prescribed regimen diligently.

Dosage: The dosage of Lenvima varies based on the type of cancer being treated, the patient’s overall health, and individual factors. The healthcare professional will determine the appropriate dosage for the specific condition.

Storage Conditions: Lenvima capsules should be stored at room temperature, protected from light and moisture. It is important to keep the medication out of reach of children and pets. Check the packaging for any specific storage instructions.

Mechanism of Action: Lenvatinib is a tyrosine kinase inhibitor that works by inhibiting multiple receptors involved in tumor angiogenesis and progression. It targets vascular endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptors, and other signaling pathways, thereby impeding the growth and spread of cancer cells.

Precautions:

• Lenvima should only be used under the supervision of a qualified healthcare professional.
• Regular monitoring of blood pressure, thyroid function, and other relevant parameters may be necessary during treatment.
• Patients with a history of cardiovascular disease or bleeding disorders should use Lenvima with caution.

Contraindications: Lenvima is contraindicated in individuals with a known hypersensitivity to lenvatinib or any of the other components of the product. Pregnant and breastfeeding women should consult their healthcare provider before using this medication.

Interactions: Lenvima may interact with certain medications, including anticoagulants and certain antiarrhythmic drugs. Inform the healthcare provider about all medications being taken, including prescription and over-the-counter drugs, as well as herbal supplements.

Overdose: In case of an overdose, seek immediate medical attention. Symptoms may include increased risk of side effects and complications related to the targeted pathways.

Side Effects: Common side effects of Lenvima may include hypertension, fatigue, diarrhea, decreased appetite, and nausea. Serious side effects, such as liver problems or severe bleeding, should be reported to the healthcare provider promptly.

As with any medication, individual responses can vary, and it is crucial to consult with a healthcare professional for personalized advice and guidance.